July 12, 2018
[vc_row][vc_column][vc_column_text]The Drug Development IPO market enjoyed a strong second quarter, with over $2.54B raised by 26 companies across the globe. 85% of companies that listed during […]
January 23, 2018
[vc_row][vc_column][vc_column_text]The Food and Drug Administration recently announced the first ever approval of a directly administered gene therapy in the United States. Spark Therapeutics one-time gene therapy […]
October 24, 2017
[vc_row][vc_column][vc_column_text] Philadelphia-based Spark Therapeutics recently received unanimous backing from an FDA advisory panel for Luxturna™, a one-shot gene therapy treatment for biallelic RPE65-mediated inherited retinal dystrophy […]